Kura Oncology (NASDAQ:KURA) Stock Rating Lowered by Wall Street Zen

Kura Oncology (NASDAQ:KURA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued reports about the company. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. UBS Group lifted their target price on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Tuesday, January 13th. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $8.31 on Friday. The firm has a 50 day moving average of $9.38 and a 200 day moving average of $9.20. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $723.14 million, a price-to-earnings ratio of -3.35 and a beta of 0.23. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $12.49.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 7,142 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the sale, the senior vice president directly owned 145,167 shares of the company’s stock, valued at $1,228,112.82. This trade represents a 4.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the sale, the insider owned 226,931 shares in the company, valued at approximately $1,919,836.26. The trade was a 4.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. IFP Advisors Inc increased its holdings in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP grew its position in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.